Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13383928 | 0.84 | ALDH1A1 (0.48) | ALDH1A1PARP1ADORA3MAPTKDM4E | |
| SCHEMBL6366687 | 0.80 | PARP1 (0.42) | ALDH1A1PARP1ADORA3TNKS2TYMS | |
| SCHEMBL12020719 | 0.79 | ALDH1A1 (0.47) | ALDH1A1PARP1ADORA3MAPTKDM4E | |
| SCHEMBL3711999 | 0.79 | DAO (0.37) | ALDH1A1PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL9144166 | 0.79 | PDE3B (0.36) | ALDH1A1PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL2541923 | 0.79 | FABP6 (0.46) | ALDH1A1PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL6142611 | 0.79 | ALDH1A1 (0.40) | ALDH1A1PARP1ADORA3MAPTKDM4E | |
| SCHEMBL22349154 | 0.79 | KDM4E (0.43) | ALDH1A1PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL22011133 | 0.79 | CSNK2A1 (0.39) | ALDH1A1PARP1ADORA3MAPTKDM4E | |
| SCHEMBL13351382 | 0.79 | ALDH1A1 (0.47) | ALDH1A1PARP1ADORA3PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054664-A1 | METABOLIC SUPPLEMENT FORMULATION AND METHODS OF USE FOR TREATING DEPRESSION AND ANXIETY | HAWKINS GERMAINE BERNARD (US) | 2020-02-20 | — | — | US | claimed |
| EP-2445518-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | OSIRIS THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2320728-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010088287-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | GEBHARD JOHN R (US) | 2010-08-05 | — | — | WO | claimed |
| JP-2010509488-A | — | — | 2010-03-25 | — | — | JP | claimed |
| WO-2010011662-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | INFLABLOC PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | OSIRIS THERAPEUTICS, INC | 2010-01-21 | — | — | US | claimed |
| EP-2139469-A2 | COBALAMIN TAXANE BIOCONJUGATES | Inflabloc Pharmaceuticals, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| CN-1126436-A | Vitamin B12 mediated oral delivery systems for GCSF and EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| EP-0700295-A1 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-13 | — | — | EP | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027613-A1 | VITAMIN B12 MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | TTR, BTD, MTHFD1 | ALDH1A1 283/4885PARP1 438/4885ADORA3 1214/4885 |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | TTR, BTD, MTHFD1 | ALDH1A1 283/4885PARP1 438/4885ADORA3 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.